RecruitingNot ApplicableNCT07599982

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

Sponsor

DreaMed Diabetes

Enrollment

102 participants

Start Date

May 25, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes (T1D)Type 2 Diabetes (T2D)

Summary

A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called MODI Algorithm for people with type 1 diabetes (t1d) and type 2 diabetes (t2d). The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMODI Algorithm

All participants use MODI insulin titration algorithm. Includes Diary app used to view treatment plans shared by MODI and manually log events (insulin intake, meal, physical activity and others) by participants; also includes a bolus calculator.